Beata Bodi
Overview
Explore the profile of Beata Bodi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
134
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bodi B, Vago R, Nagy L, Raduly A, Gulyas A, Kupecz K, et al.
Int J Mol Sci
. 2025 Mar;
26(5).
PMID: 40076880
Uremic cardiomyopathy, characterized by diastolic dysfunction, left ventricular hypertrophy (LVH), and fibrosis, is a common cardiovascular complication of chronic kidney disease (CKD). Men are at a higher risk for cardiovascular...
2.
Raduly A, Nagy L, Bodi B, Papp Z, Borbely A
ESC Heart Fail
. 2024 Nov;
PMID: 39545304
No abstract available.
3.
Szoke K, Bodi B, Hendrik Z, Czompa A, Gyongyosi A, Haines D, et al.
Pharmacol Res Perspect
. 2023 May;
11(3):e01091.
PMID: 37190667
Previous investigations have demonstrated that treatment of animals with rapamycin increases levels of autophagy, which is a process by which cells degrade intracellular detritus, thus suppressing the emergence of senescent...
4.
Bodi B, Olah A, Martha L, Toth A, Radovits T, Merkely B, et al.
Rev Cardiovasc Med
. 2021 Dec;
22(4):1079-1085.
PMID: 34957754
Although the knowledge of sports cardiology advanced significantly in the recent years, the molecular mechanisms by which exercise training augments cardiac performance is poorly understood. Here we aimed at determining...
5.
Bodi B, Kovacs A, Gulyas H, Martha L, Toth A, Matyas C, et al.
Antioxidants (Basel)
. 2021 Nov;
10(11).
PMID: 34829647
Heart failure with preserved ejection fraction (HFpEF) and right ventricular (RV) dysfunction are frequent complications of diabetic cardiomyopathy. Here we aimed to characterize RV and left ventricular (LV) remodeling and...
6.
Bodi B, Pilz P, Martha L, Lang M, Hamza O, Fagyas M, et al.
Int J Mol Sci
. 2021 Oct;
22(20).
PMID: 34681724
Post-ischemic left ventricular (LV) remodeling and its hypothetical prevention by repeated remote ischemic conditioning (rRIC) in male Sprague-Dawley rats were studied. Myocardial infarction (MI) was evoked by permanent ligation of...
7.
Kovacs A, Herwig M, Budde H, Delalat S, Kolijn D, Bodi B, et al.
Antioxidants (Basel)
. 2021 Jul;
10(6).
PMID: 34208541
Standard heart failure (HF) therapies have failed to improve cardiac function or survival in HF patients with right ventricular (RV) dysfunction suggesting a divergence in the molecular mechanisms of RV...
8.
Fulop G, Olah A, Csipo T, Kovacs A, Porszasz R, Veress R, et al.
Basic Res Cardiol
. 2021 Apr;
116(1):24.
PMID: 33844095
Omecamtiv mecarbil (OM) is a promising novel drug for improving cardiac contractility. We tested the therapeutic range of OM and identified previously unrecognized side effects. The Ca sensitivity of isometric...
9.
Lodi M, Banhegyi V, Bodi B, Gyongyosi A, Kovacs A, Arokszallasi A, et al.
J Transl Med
. 2020 Dec;
18(1):470.
PMID: 33298102
Background: Cardiomyopathy is a common side effect of doxorubicin (DOX) chemotherapy. Despite intensive research efforts in the field, there is still no evidence available for routine cardioprotective prophylaxis to prevent...
10.
Lodi M, Priksz D, Fulop G, Bodi B, Gyongyosi A, Nagy L, et al.
J Transl Med
. 2019 Jul;
17(1):229.
PMID: 31324258
Background: Chemotherapy-induced left ventricular dysfunction represents a major clinical problem, which is often only recognised at an advanced stage, when supportive therapy is ineffective. Although an early heart failure treatment...